Your activity: 262 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Clonazepam: Drug information

Clonazepam: Drug information
(For additional information see "Clonazepam: Patient drug information" and see "Clonazepam: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Risk from concomitant use with opioids:

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Abuse, misuse, and addiction:

The use of benzodiazepines, including clonazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing clonazepam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.

Dependence and withdrawal reactions:

The continued use of benzodiazepines, including clonazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clonazepam after continued use may precipitate acute withdrawal reactions, which can be life threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam or reduce the dosage.

Brand Names: US
  • KlonoPIN
Brand Names: Canada
  • APO-ClonazePAM;
  • Clonapam;
  • CO ClonazePAM [DSC];
  • DOM-ClonazePAM [DSC];
  • DOM-ClonazePAM-R [DSC];
  • MYLAN-ClonazePAM [DSC];
  • PMS-ClonazePAM;
  • PMS-ClonazePAM-R;
  • PRO-ClonazePAM;
  • RIVA-ClonazePAM;
  • Rivotril;
  • SANDOZ ClonazePAM [DSC];
  • TEVA-ClonazePAM [DSC]
Pharmacologic Category
  • Anticonvulsant, Benzodiazepine;
  • Benzodiazepine
Dosing: Adult

Note: Reduce dose or avoid use in patients receiving opioids, with significant chronic disease (eg, respiratory compromise), or at increased risk for accumulation (eg, hepatic impairment). Generally, avoid use in patients with, or at risk for, substance use disorders; if prescribed, closely supervise use.

Anxiety

Anxiety:

Anxiety and agitation, acute (adjunctive therapy or monotherapy) (off-label use):

Oral: Initial: 0.5 mg/day in 2 divided doses; may be given as needed or scheduled (Fang 2012; Marder 2020; Mojtabai 2020; manufacturer's labeling). May increase dose based on response and tolerability up to 4 mg/day in 2 to 4 divided doses (Roy-Byrne 2020b; manufacturer's labeling). In severe agitation due to psychosis, some experts consider further increasing dose, if needed and tolerated, up to a reported maximum of 8 mg/day in divided doses (Fang 2012).

Anxiety disorder (adjunctive therapy or monotherapy) (alternative agent):

Note: While FDA-approved for panic disorder, clinical trials also support use in other anxiety disorders (Pollack 2014; Wang 2016). Generally used short-term for symptom relief until concurrent therapy is effective (eg, ≤12 weeks). Long-term, low-dose therapy may be used for select patients when other treatments are ineffective or poorly tolerated (Katzman 2014; WFSBP [Bandelow 2012]). Use with caution in patients with posttraumatic stress disorder; benzodiazepines may worsen symptoms (VA/DoD 2017).

Oral: Initial: 0.25 to 1 mg/day in 1 to 2 divided doses; may be given as needed or scheduled. If needed, may increase daily dose based on response and tolerability in increments of 0.25 to 0.5 mg every few days (eg, ≥3 days); usual target range: 1 to 3 mg/day; maximum: 4 mg/day in 1 to 4 divided doses. To minimize daytime motor impairment and drowsiness, may be taken as a single dose at bedtime (Bystritsky 2020; Roy-Byrne 2020a; Roy-Byrne 2020b; Stein 2020; manufacturer's labeling).

Myoclonus

Myoclonus (monotherapy or adjunctive therapy) (off-label use):

Oral: Initial: 0.5 mg/day in 2 divided doses; may gradually increase daily dose based on response and tolerability to a usual dose of 1.5 to 3 mg/day in 3 divided doses (Caviness 2020; Jankovic 1986; Obeso 1989; Tijssen 1997).

Rapid eye movement sleep behavior disorder

Rapid eye movement sleep behavior disorder (monotherapy or adjunctive therapy) (off-label use):

Oral: Initial: 0.25 to 0.5 mg within 30 minutes of bedtime; usual dose range: 0.25 to 2 mg before bedtime (AASM [Aurora 2010]; Howell 2021). In most patients, 0.5 to 1 mg before bedtime is sufficient and better tolerated than doses >1 mg (Howell 2021).

Note: In patients with dementia, gait disorders, or obstructive sleep apnea, avoid use or reduce dose (eg, initial dose: 0.125 to 0.25 mg before bedtime) (AASM [Aurora 2010]; Fernández-Arcos 2016; Li 2016).

Seizure disorders, refractory

Seizure disorders, refractory (adjunctive therapy or monotherapy) (alternative agent):

Note: FDA-approved for Lennox-Gastaut syndrome and resistant absence seizures; however, also used off label as adjunctive or bridge therapy in other seizure types, including myoclonic and atonic seizures and drug-resistant epilepsy syndromes (Bank 2017; Schachter 2020).

Oral:

Monotherapy: Initial: 0.5 to 1.5 mg/day in 1 to 3 divided doses (Brodie 1997; manufacturer's labeling).

Adjunctive therapy: Initial: 0.5 to 1 mg/day in 1 to 3 divided doses (Schachter 2020).

Dosage adjustment: May increase dose based on response and tolerability in increments of 0.5 to 1 mg every 3 to 7 days to usual maintenance dose of 2 to 8 mg/day in 1 to 2 divided doses; maximum dose: 20 mg/day (Brodie 1997; Schachter 2020; manufacturer's labeling).

Tardive dyskinesia

Tardive dyskinesia (alternative agent) (off-label use):

Note: For reduction of dyskinesia and anxiety in milder forms of tardive dyskinesia in conjunction with appropriate therapy modification(s) such as tapering/discontinuing offending drug (Liang 2021).

Oral: Initial: 0.5 mg/day; increase daily dose based on response and tolerability by 0.5 mg every 5 days up to 4 mg/day (Liang 2021; Thaker 1990).

Vertigo, acute episodes, treatment

Vertigo, acute episodes, treatment (alternative agent) (off-label use):

Note: Reserve use for episodes lasting several hours to days.

Oral: 0.25 to 0.5 mg every 8 to 12 hours as needed for 24 to 48 hours (Furman 2021; Ganança 2002).

Discontinuation of therapy: In patients receiving extended or higher-dose benzodiazepine therapy, unless safety concerns require a more rapid withdrawal, gradually withdraw to detect reemerging symptoms and minimize rebound and withdrawal symptoms. Taper total daily dose by 10% to 50% every 1 to 2 weeks based on response and tolerability (Bystritsky 2020; Park 2021; VA/DoD 2015). The optimal taper rate and duration will vary; durations up to 6 months may be necessary for some patients. For patients on high doses, taper more rapidly in the beginning and slow the reduction rate as the taper progresses. For example, reduce the dose weekly by 25% until half of the dose remains. Thereafter, continue to reduce by ~12% every 4 to 7 days (VA/DoD 2015).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Clonazepam metabolites may accumulate in patients with renal impairment.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Clonazepam undergoes hepatic metabolism. Contraindicated in patients with significant hepatic impairment.

Dosing: Pediatric

(For additional information see "Clonazepam: Pediatric drug information")

Note: If necessary to discontinue clonazepam therapy, drug should be withdrawn gradually.

Neuroirritability, agitation (palliative care): Limited data available: Infants, Children, and Adolescents: Oral:

Patient weight:

<30 kg: Initial: 0.01 to 0.03 mg/kg/day in divided doses up to 3 to 4 times daily; increase dose to desired effect up to a maximum daily dose: 0.2 mg/kg/day in 3 divided doses (Kliegman 2017; Wustoff 2007)

≥30 kg: Initial: ≤0.25 mg/dose 3 times daily; may increase by 0.5 to 1 mg/day every 3 days up to maintenance dose range: 0.05 to 0.2 mg/kg/day up to maximum daily dose: 20 mg/day (Kliegman 2017)

Seizure disorders:

Infants and Children <10 years or ≤30 kg: Oral:

Initial: 0.01 to 0.03 mg/kg/day in 2 to 3 divided doses; maximum initial daily dose: 0.05 mg/kg/day; increase by ≤0.25 to 0.5 mg every third day until seizures are controlled or adverse effects observed

Maintenance dose: 0.1 to 0.2 mg/kg/day in 3 divided doses; maximum daily dose: 0.2 mg/kg/day

Children ≥10 years or >30 kg and Adolescents: Oral:

Initial: 0.01 to 0.05 mg/kg/day in 2 or 3 divided doses; maximum initial dose: 0.5 mg/dose 3 times daily; may increase dose by 25% or by 0.5 to 1 mg every 3 to 7 days until seizures are controlled or adverse effects observed (Kliegman 2017)

Maintenance dose range: 0.05 to 0.2 mg/kg/day in 2 to 3 divided doses; maximum daily dose: 20 mg/day (Kliegman 2017)

Panic disorder: Adolescents ≥18 years: Oral: Initial: 0.25 mg twice daily; increase in increments of 0.125 to 0.25 mg twice daily every 3 days; target dose: 1 mg/day in divided doses; some patients may require higher doses up to a maximum daily dose: 4 mg/day. To discontinue, treatment should be withdrawn gradually; decrease dose by 0.125 mg twice daily every 3 days until medication is completely withdrawn.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Clonazepam metabolites may accumulate in patients with renal impairment.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Clonazepam undergoes hepatic metabolism. Contraindicated in patients with significant hepatic impairment.

Dosing: Older Adult

Refer to adult dosing. Initiate with low doses and observe closely.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

KlonoPIN: 0.5 mg [contains corn starch, fd&c yellow #6 aluminum lake]

KlonoPIN: 0.5 mg [DSC] [scored; contains fd&c yellow #6 aluminum lake]

KlonoPIN: 1 mg [contains corn starch, fd&c blue #1 aluminum lake, fd&c blue #2 aluminum lake]

KlonoPIN: 1 mg [contains fd&c blue #1 aluminum lake, fd&c blue #2 aluminum lake]

KlonoPIN: 2 mg [DSC]

KlonoPIN: 2 mg [contains corn starch]

Generic: 0.5 mg, 1 mg, 2 mg

Tablet Disintegrating, Oral:

Generic: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Rivotril: 0.5 mg, 2 mg

Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg

Controlled Substance

C-IV

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017533s059lbl.pdf#page=19, must be dispensed with this medication.

Administration: Adult

To reduce somnolence, administration of one dose at bedtime may be desirable.

Orally disintegrating tablet: Open pouch and peel back foil on the blister; do not push tablet through foil. Use dry hands to remove tablet and place in mouth. May be swallowed with or without water. Use immediately after removing from package.

Tablet: Swallow whole with water.

Administration: Pediatric

Oral: To reduce somnolence, administration of one dose at bedtime may be desirable.

Orally disintegrating tablet: Open pouch and peel back foil on the blister; do not push tablet through foil. Use dry hands to remove tablet and place in mouth. May be swallowed with or without water. Use immediately after removing from package.

Tablet: Swallow whole with water

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 3]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.

NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).

Use: Labeled Indications

Panic disorder: Treatment of panic disorder, with or without agoraphobia.

Seizure disorders: Monotherapy or adjunctive therapy in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures; absence seizures (petit mal) unresponsive to succinimides.

Use: Off-Label: Adult

Anxiety and agitation, acute; Anxiety disorder; Myoclonus; Rapid eye movement sleep behavior disorder; Tardive dyskinesia; Vertigo, acute episodes, treatment

Medication Safety Issues
Sound-alike/look-alike issues:

ClonazePAM may be confused with ALPRAZolam, cloBAZam, cloNIDine, clorazepate, cloZAPine, LORazepam

KlonoPIN may be confused with cloNIDine, clorazepate, cloZAPine, LORazepam

Geriatric Patients: High-Risk Medication:

Beers Criteria: Clonazepam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use. Older adults also have a slower metabolism of long-acting benzodiazepines (eg, clonazepam). However, clonazepam may be appropriate in the elderly when used for seizure disorders, rapid eye movement sleep behavior disorders, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2019]).

Adverse Reactions (Significant): Considerations
Anterograde amnesia

Benzodiazepines can impair explicit memory and produce anterograde amnesia (ie, memory of information or events after drug administration). Retrograde amnesia (ie, events or information prior to drug administration) is unaffected. However, the magnitude of the amnesic effect from benzodiazepines differs among the various agents, depending on their pharmacokinetic/pharmacodynamic properties, route of administration, and dose. Anterograde amnesia is associated with higher doses, IV administration, and benzodiazepines with faster absorption and higher potency (Ref).

Mechanism: Dose-related (Ref). Benzodiazepines, including clonazepam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. The GABA-A receptor complex has subunits, including a benzodiazepine-binding site, which is classified into several types. The BZ1 receptor type, specifically, which is highly concentrated in the cortex, thalamus, and cerebellum, is responsible for benzodiazepine-associated anterograde amnesia (Ref). Of note, clonazepam has a relatively weaker binding affinity for GABA-A receptors compared to other high-potency benzodiazepines (Ref).

Onset: Rapid; during chronic benzodiazepine administration, tolerance appears to develop, and memory impairment is limited to a window of 90 minutes following each dose (Ref)

Risk factors:

• Specific benzodiazepine: Clonazepam, despite its high potency, is less likely to cause anterograde amnesia due to its low lipid solubility (resulting in slower absorption) (Ref)

CNS effects

Clonazepam can cause significant drowsiness and fatigue. Tolerance usually develops to its sedative effects. In addition, clonazepam has been shown to cause ataxia (usually transient) and psychomotor impairment (Ref). Benzodiazepines, in general, are associated with an increased risk of motor vehicle accidents and falls (particularly in older adults) (Ref).

Mechanism: Sedation is dose-dependent (Ref); benzodiazepines, including clonazepam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. The GABA-A receptor complex has subunits, including a benzodiazepine-binding site, which is classified into several types. The BZ1 receptor, specifically, which is highly concentrated in the cortex, thalamus, and cerebellum, is responsible for benzodiazepine-associated sedation (Ref).

Risk factors:

Sedating effects:

• Older adults (Ref)

• Higher doses (Ref)

• Titrating the initial dose too rapidly (gradual titration and dividing the dosing is preferred) (Ref)

• Concomitant use of other CNS depressants (Ref)

Paradoxical reactions

Paradoxical reactions, sometimes referred to as disinhibitory reactions or behavioral disinhibition, have been reported in children, adults, and older adults with benzodiazepine use, particularly in those with risk factors. Reactions are relatively uncommon and have been characterized in a number of ways, including increased talkativeness, excitement, restlessness, hyperactivity, sleep disturbances, hostility, rage, agitation, and/or aggressive behavior (Ref). In children, paradoxical reactions to benzodiazepines, particularly midazolam, have been most commonly described as agitation, restlessness, inconsolable crying, screaming, disorientation, and/or excitement (Ref).

Mechanism: Dose-related (potentially, although may also be idiosyncratic); exact mechanism is unclear due to limited evidence (Ref). One hypothesis has suggested that increased GABAergic activity in the brain from benzodiazepines causes a decrease in the restraining influence of the frontal cortex, thereby causing excitement, hostility, and rage. An additional proposed mechanism is that benzodiazepines can reduce 5HT (serotonin) neurotransmission, subsequently causing aggressive behavior. Another mechanism is that in select patients with genetic variations in the gamma-aminobutyric acid (GABA) receptor, there is decreased GABA transmission with benzodiazepines which results in neuronal overexcitation manifested clinically as a paradoxical reaction (Ref).

Risk factors:

Benzodiazepines, in general:

Age-related (extremes of age):

• Children (Ref)

• Older adults (Ref)

Disease- or condition-related:

• Past history of aggressive behavior or violence (Ref)

• Alcoholism or history of alcohol use (Ref)

• Psychiatric or personality disorders, including affective disorder (Ref)

• Dementia (Ref)

Patient-related:

• Genetic predisposition (potential risk factor) (ie, variability in the density of the GABA-benzodiazepine receptors throughout the brain, a persistence of a juvenile pattern of benzodiazepine response in adulthood, or multiple allelic forms of the receptors with varying affinities for benzodiazepines have all been suggested as potentially playing a role) (Ref)

Other potential risk factors: Note: No established risk factors since evidence is limited (Ref)

• Higher doses (likely a risk, but not firmly established) (Ref)

• Parenteral benzodiazepine administration (potential risk) (Ref)

• Specific benzodiazepines (potential risk): Benzodiazepines with a higher potency (eg, clonazepam) and/or a short half-life (eg, alprazolam) are believed to carry an increased risk; however, it has also been suggested that there is no difference in risk among the various benzodiazepines (Ref) Of note, clonazepam is considered to have a relatively long half-life (usually reported at >24 hours for adults) (Ref)

Withdrawal syndrome

Therapeutic use of benzodiazepines, including clonazepam, is associated with a withdrawal syndrome in children and adults, particularly following abrupt or overly rapid discontinuation following regular use. Benzodiazepine-associated withdrawal symptoms can include new withdrawal symptoms or rebound symptoms, both of which are typically transient, short-lasting, and reversible. A persistent post-withdrawal disorder, which can be long-lasting, severe, and potentially irreversible, has also been described. In general, withdrawal symptoms are typically mild and characterized as anxiety, panic attacks, restlessness, insomnia and other sleep disturbances, irritability, poor concentration, confusion, nausea/vomiting, weight loss, tremor, diaphoresis, tachycardia, and muscle pain/stiffness. Severe symptoms such as seizure and psychosis may also rarely occur following abrupt discontinuation. Severe withdrawal may be fatal. Data are limited on persistent post-withdrawal disorders, but cognitive impairment; depression; anxiety; sensory disturbances (eg, tinnitus, paresthesia, skin sensations); motor disturbances (eg, muscle pain, weakness, spasms); and GI disturbances have been described (Ref). For clonazepam specifically, there are also rare case reports of new-onset withdrawal catatonia occurring after abrupt withdrawal of chronic therapy (Ref). Severity, onset, and duration of any benzodiazepine withdrawal syndrome varies based on several factors, such as specific benzodiazepine administered (and its half-life), dose, and duration of use. However, in general, new withdrawal symptoms typically resolve within 2 to 4 weeks and rebound symptoms may last 3 weeks, but persistent post-withdrawal symptoms may last >6 weeks and take 6 to 12 months to completely resolve, and in some cases, persist for years (Ref).

Mechanism: Withdrawal; exact mechanisms are complex and unclear, but chronic exposure to benzodiazepines alters GABAergic neurotransmission (up/down regulation of gamma-aminobutyric acid [GABA]-A receptor subunits) and rapid or abrupt withdrawal results in underactivity of inhibitory GABA functions subsequently increasing excitatory nervous activity and likely contributing to symptoms associated with withdrawal (Ref). A role of glutamate receptors, including N-methyl-D aspartate (NMDA)-, non-NMDA-receptors, and metabotropic glutamate (mGlu) receptors, has also been suggested. In mice and rat studies, antagonists for NMDA, non-NMDA, and group 1 mGluRs have shown the ability to potently suppress the withdrawal signs caused by chronic benzodiazepine administration (Ref).

Onset: Varied; onset of symptoms usually occurs within the first day following abrupt withdrawal of short- or intermediate-acting benzodiazepines (such a lorazepam). Long-acting benzodiazepines (such as diazepam) are usually associated with an initial onset of withdrawal symptoms 5 days following abrupt discontinuation (Ref). Due to clonazepam’s longer half-life (range in adults: 17 to 60 hours) and slower elimination, clonazepam is usually associated with withdrawal symptoms that are more delayed in onset; in a small number of patients receiving clonazepam for seven consecutive nights for insomnia, significant rebound insomnia was observed on the third withdrawal night following abrupt discontinuation (Ref). In general, persistent post-withdrawal disorder associated with psychotropic medications (eg, benzodiazepines) have an onset ranging from 24 hours to 6 weeks following a decrease, discontinuation, or switch (Ref).

Risk factors:

Benzodiazepines, in general:

• Abrupt discontinuation (rather than gradual dosage reduction) of a benzodiazepine used long-term (Ref)

• Higher doses (Ref)

• Chronic dosing (ie, intermittent dosing may reduce the risk of withdrawal symptoms) (Ref)

• Withdrawal-associated seizure: Predisposed patients (eg, brain damage, alcohol abuse, history of seizure, or those taking medications that lower the seizure threshold) (Ref)

Clonazepam specifically:

• Specific benzodiazepine: Benzodiazepines with a relatively longer half-life (usually reported at >24 hours in adults), such as clonazepam, are usually associated with fewer (and potentially less severe) rebound and withdrawal symptoms, particularly if tapered appropriately. High-potency benzodiazepines with short and intermediate half-lives generally have a higher risk for rebound, withdrawal reactions, and dependence compared to long-acting agents (Ref)

• Ultraslow acetylation of the clonazepam metabolite by the N-acetyltransferase (NAT2) enzyme (potential risk factor; single case report) (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions reported in patients with panic disorder, unless otherwise noted.

>10%: Nervous system: Ataxia (seizure disorder: ~30%; panic disorder: 1% to 9%) (table 1), behavioral problems (seizure disorder: ~25%), dizziness (5% to 12%), drowsiness (seizure disorder: ~50%; panic disorder: 26% to 50%) (table 2)

Clonazepam: Adverse Reaction: Ataxia

Drug (Clonazepam)

Placebo

Population

Dose

Indication

Number of Patients (Clonazepam)

Number of Patients (Placebo)

Comments

8%

0%

Adults

≥3 mg/day

Panic disorder

235

294

N/A

8%

0%

Adults

2 to <3 mg/day

Panic disorder

113

294

N/A

2%

0%

Adults

<1 mg/day

Panic disorder

96

294

N/A

1%

0%

Adults

1 to <2 mg/day

Panic disorder

129

294

N/A

9%

0%

Adults

≥3 mg/day

Panic disorder

235

294

Defined as "coordination abnormal"

7%

0%

Adults

2 to <3 mg/day

Panic disorder

113

294

Defined as "coordination abnormal"

2%

0%

Adults

1 to <2 mg/day

Panic disorder

129

294

Defined as "coordination abnormal"

1%

0%

Adults

<1 mg/day

Panic disorder

96

294

Defined as "coordination abnormal"

~30%

N/A

N/A

N/A

Seizure disorder

N/A

N/A

N/A

Clonazepam: Adverse Reaction: Drowsiness

Drug (Clonazepam)

Placebo

Population

Dose

Indication

Number of Patients (Clonazepam)

Number of Patients (Placebo)

50%

10%

Adults

2 to <3 mg/day

Panic disorder

113

294

36%

10%

Adults

≥3 mg/day

Panic disorder

235

294

35%

10%

Adults

1 to <2 mg/day

Panic disorder

129

294

26%

10%

Adults

<1 mg/day

Panic disorder

96

294

~50%

N/A

N/A

N/A

Seizure disorder

N/A

N/A

1% to 10%:

Endocrine & metabolic: Decreased libido (1% to 3%)

Gastrointestinal: Abdominal pain (2%), constipation (3% to 5%), decreased appetite (3%)

Genitourinary: Dysmenorrhea (3% to 6%), impotence (≤3%), urinary frequency (1% to 2%), urinary tract infection (2%), vaginitis (2% to 4%)

Hypersensitivity: Hypersensitivity reaction (2% to 4%)

Infection: Influenza (4% to 5%)

Nervous system: Confusion (1% to 2%), delayed ejaculation (1% to 2%), depression (6% to 8%), dysarthria (2% to 4%), emotional lability (2%), fatigue (6% to 9%), (table 3) memory impairment (4% to 5%), nervousness (3% to 4%), reduced intellectual ability (2% to 4%)

Clonazepam: Adverse Reaction: Fatigue

Drug (Clonazepam)

Placebo

Population

Dose

Indication

Number of Patients (Clonazepam)

Number of Patients (Placebo)

9%

4%

Adults

<1 mg/day

Panic disorder

96

294

7%

4%

Adults

≥3 mg/day

Panic disorder

235

294

7%

4%

Adults

2 to <3 mg/day

Panic disorder

113

294

6%

4%

Adults

1 to <2 mg/day

Panic disorder

129

294

Neuromuscular & skeletal: Myalgia (2% to 4%)

Ophthalmic: Blurred vision (2% to 3%)

Respiratory: Bronchitis (2%), cough (2% to 4%), pharyngitis (2% to 3%), rhinitis (2% to 4%), sinusitis (4% to 8%), upper respiratory tract infection (6% to 10%)

<1% (all indications):

Cardiovascular: Ankle edema, chest pain, edema, flushing, leg thrombophlebitis, orthostatic hypotension, palpitations, pedal edema

Dermatologic: Acne flare, alopecia, burning sensation of skin, cellulitis, contact dermatitis, dermal hemorrhage, dermatological reaction, excoriation of skin, pruritus, pustular rash, xeroderma

Endocrine & metabolic: Gout, increased libido, increased thirst, loss of libido, weight gain, weight loss

Gastrointestinal: Abdominal distress, ageusia, dyspepsia, flatulence, frequent bowel movements, gastric distress, gastrointestinal inflammation, heartburn, hemorrhoids, hunger, increased appetite, motion sickness, sialorrhea, toothache

Genitourinary: Bladder dysfunction, cystitis, dysuria, ejaculatory disorder, irregular menses, mastalgia, pelvic pain, urinary incontinence, urinary retention, urinary tract hemorrhage, urine discoloration

Hypersensitivity: Tongue edema

Infection: Candidiasis, fungal infection, herpes simplex infection, infectious mononucleosis, streptococcal infection, viral infection

Local: Local inflammation

Nervous system: Aggressive behavior, alcohol intoxication, ankle pain, anxiety, apathy, depersonalization, disinhibition (organic), disturbance in attention, excitement, falling, heavy headedness, hyperactive behavior, hypertonia, hypoesthesia, illusion, increased dream activity, insomnia, malaise, migraine, nightmares, outbursts of anger, pain, paresis, paresthesia, shivering, sleep disorder, slowed reaction time, suicidal ideation, twitching, twitching of eye, vertigo, yawning

Neuromuscular & skeletal: Arthralgia, back pain, bone fracture, foot pain, jaw pain, knee effusion, knee pain, lower back pain, lower extremity pain, lower limb cramp, muscle cramps, muscle strain, neck pain, shoulder pain, sprain, tendinopathy, tremor

Ophthalmic: Diplopia, eye irritation, hordeolum, periorbital edema, visual disturbance, visual field defect, xerophthalmia

Otic: Otalgia, otitis

Renal: Polyuria

Respiratory: Dyspnea, epistaxis, exacerbation of asthma, hoarseness, pleurisy, pneumonia, sneezing

Miscellaneous: Accidental injury, burn, fever, wound

Frequency not defined (all indications):

Nervous system: Drug dependence, suicidal tendencies, withdrawal syndrome

Miscellaneous: Paradoxical reaction (including, agitation, hallucination, hostility, irritability, sleep disturbance, vivid dreams)

Postmarketing (all indications):

Cardiovascular: Facial edema

Dermatologic: Skin rash (Munoli 2012)

Endocrine & metabolic: Dehydration, hirsutism

Gastrointestinal: Anorexia, coated tongue, diarrhea, encopresis, gastritis, gingival pain, nausea, xerostomia

Genitourinary: Nocturia

Hematologic & oncologic: Anemia, eosinophilia, leukopenia, lymphadenopathy, pancytopenia (Bautista-Quach 2010), thrombocytopenia (Veall 1975)

Hepatic: Hepatomegaly, increased serum alkaline phosphatase (transient), increased serum transaminases (transient)

Nervous system: Abnormal behavior (increased oppositional behavior) (Waslick 2006), anterograde amnesia, aphonia, catatonia (with withdrawal) (Oldham 2016), choreiform movements, coma, glassy-eyed appearance, headache, hemiparesis, hypotonia, hysteria, myasthenia, parasomnias (sleep-related eating disorder) (Ghosh 2018), psychomotor impairment (Wilden 1990), psychosis, slurred speech

Neuromuscular & skeletal: Dysdiadochokinesia, muscle injury (myotoxicity) (Han 2019)

Ophthalmic: Abnormal eye movements, nystagmus disorder

Respiratory: Chest congestion, respiratory depression (Channing 2012), rhinorrhea, upper respiratory system symptoms (hypersecretion)

Miscellaneous: Physical health deterioration

Contraindications

Hypersensitivity to clonazepam, other benzodiazepines, or any component of the formulation; significant liver disease; acute narrow-angle glaucoma

Canadian labeling: Additional contraindications (not in US labeling): Severe respiratory insufficiency; sleep apnea syndrome; myasthenia gravis

Warnings/Precautions

Concerns related to adverse effects:

• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).

• Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.

Disease-related concerns:

• Depression: Use caution in patients with depression, particularly if suicidal risk may be present.

• Glaucoma: May be used in patients with open angle glaucoma who are receiving appropriate therapy; contraindicated in acute narrow angle glaucoma.

• Hepatic impairment: Use with caution in patients with hepatic impairment; accumulation likely to occur. Contraindicated in patients with significant hepatic impairment.

• Porphyria: Use with caution in patients with porphyria; may have a porphyrogenic effect.

• Renal impairment: Use with caution in patients with renal impairment; clonazepam metabolites are renally eliminated.

• Respiratory disease: Clonazepam may cause respiratory depression and may produce an increase in salivation; use with caution in patients with compromised respiratory function (eg, chronic obstructive pulmonary disease, sleep apnea) and in patients who have difficulty handling secretions.

Concurrent drug therapy issues:

• Flumazenil: Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.

Special populations:

• Debilitated patients: Use with caution in debilitated patients.

• Elderly patients: Elderly patients may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in elderly dementia patients (Jennum 2015; Saarelainen 2018).

• Fall risk: Use with extreme caution in patients who are at risk of falls.

Dosage form specific issues:

• Phenylalanine: Some products contain phenylalanine.

Other warnings/precautions:

• Abuse, misuse, and addiction: Counsel patients at increased risk on proper use and monitoring for signs and symptoms of abuse, misuse, and addiction. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required.

• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Worsening of seizures may occur when added to patients with multiple seizure types. Loss of anticonvulsant activity may occur (typically within 3 months of initiation); dose adjustment may be necessary. Periodically reevaluate the long-term usefulness of clonazepam for the individual patient.

• Tolerance: Clonazepam is a long half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the anticonvulsant effects. It does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.

Metabolism/Transport Effects

Substrate of CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Risk D: Consider therapy modification

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

Cosyntropin: May enhance the hepatotoxic effect of ClonazePAM. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of ClonazePAM. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of ClonazePAM. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Risk C: Monitor therapy

Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Melatonin: May enhance the sedative effect of Benzodiazepines. Risk C: Monitor therapy

Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone. Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution. Risk D: Consider therapy modification

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine. Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended. Risk C: Monitor therapy

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. Risk X: Avoid combination

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Teduglutide: May increase the serum concentration of Benzodiazepines. Risk C: Monitor therapy

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines. Risk C: Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Vigabatrin: May enhance the CNS depressant effect of ClonazePAM. Vigabatrin may increase the serum concentration of ClonazePAM. Risk C: Monitor therapy

Yohimbine: May diminish the therapeutic effect of Antianxiety Agents. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Pregnancy Considerations

Clonazepam crosses the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and “floppy infant syndrome” (which also includes withdrawal symptoms) has been reported with some benzodiazepines, including clonazepam (Bergman 1992; Iqbal 2002; Wikner 2007). A combination of factors influences the potential teratogenicity of anticonvulsant therapy. When treating pregnant females with epilepsy, monotherapy with the lowest effective dose and avoidance medications known to have a high incidence of teratogenic effects is recommended (Harden 2009; Wlodarczyk 2012). When treating pregnant females with panic disorder, psychosocial interventions should be considered prior to pharmacotherapy (APA 2009).

Patients exposed to clonazepam during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.

Breastfeeding Considerations

Clonazepam is present in breast milk.

The relative infant dose (RID) of clonazepam is 2.8% when calculated using the highest breast milk concentration from a case report and compared to a weight-adjusted maternal dose of 4 mg/day.

In general, breastfeeding is considered acceptable when an RID of a medication is <10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is <5% for psychotropic agents (Larsen 2015).

The RID of clonazepam was calculated using a milk concentration of 0.0107 mcg/mL, providing an estimated daily infant dose via breast milk of 1.6 mcg/kg/day. This milk concentration was obtained following maternal administration of clonazepam 2 mg twice daily during pregnancy and after delivery; milk samples were obtained on days 2 to 4 postpartum (Söderman 1988). Slightly higher milk concentrations (0.013 mcg/mL) were noted in a second report. The mother was taking clonazepam throughout pregnancy (dose not specified); milk sampling began 72 hours after delivery (Fisher 1985). Clonazepam was detected in the serum of the breastfeeding infants (Fisher 1985; Söderman 1988) and concentrations may have been influenced not only by breast milk but also by in utero exposure.

Apnea, CNS depression, hypotonia, and somnolence have been reported in infants exposed to clonazepam via breast milk (Fisher 1985; Kelly 2012; Soussan 2014). In a review of females taking various doses of clonazepam (range: 0.5 to 2 mg/day) during pregnancy and postpartum (n=10) or only postpartum (n=1), clonazepam was measurable in the serum of two infants; however, adverse events were not reported (Birnbaum 1999).

Clonazepam has a long half-life and may accumulate in the breastfed infant, especially preterm infants or those exposed to chronic maternal doses (Davanzo 2013). A single maternal dose may be compatible with breastfeeding (WHO 2002). If chronic use of a benzodiazepine is needed in breastfeeding females, use of shorter acting agents is preferred (Davanzo 2013; Veiby 2015; WHO 2002). Infants of females using medications for seizure disorders should be monitored for drowsiness, decreased feeding, and poor weight gain (Veiby 2015). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Dietary Considerations

Some products may contain phenylalanine.

Monitoring Parameters

Mental alertness, CBC, liver and renal function tests (periodically with long-term therapy), suicidality (eg, suicidal thoughts, depression, behavioral changes).

Reference Range

Relationship between serum concentration and dose is not well established. Therapeutic doses have been associated with serum concentrations of ~20 to 70 ng/mL (Patsalos 2018).

Mechanism of Action

The exact mechanism is unknown, but believed to be related to its ability to enhance the activity of GABA; suppresses the spike-and-wave discharge in absence seizures by depressing nerve transmission in the motor cortex.

Pharmacokinetics

Onset of action: ~20 to 40 minutes (Hanson 1972).

Duration: Infants and young children: 6 to 8 hours (Hanson 1972); Adults: ≤12 hours (Hanson 1972).

Absorption: Rapidly and completely absorbed.

Distribution: Children: Vd: 1.5 to 3 L/kg (Walson 1996); Adults: Vd: 1.5 to 6.4 L/kg (Walson 1996).

Protein binding: ~85%.

Metabolism: Extensively hepatic via glucuronide and sulfate conjugation; undergoes nitroreduction to 7-aminoclonazepam, followed by acetylation to 7-acetamidoclonazepam; nitroreduction and acetylation are via CYP3A4; metabolites undergo glucuronide and sulfate conjugation (Patsalos 2018).

Bioavailability: ~90%.

Half-life elimination: Neonates: 22 to 81 hours (Patsalos 2018); Children: 22 to 33 hours (Walson 1996); Adults: 17 to 60 hours (Walson 1996).

Time to peak, serum: 1 to 4 hours.

Excretion: Urine (<2% as unchanged drug); metabolites excreted as glucuronide or sulfate conjugates.

Pricing: US

Tablet, orally-disintegrating (clonazePAM Oral)

0.125 mg (per each): $1.30

0.25 mg (per each): $1.30

0.5 mg (per each): $1.30

1 mg (per each): $1.48

2 mg (per each): $2.05

Tablets (clonazePAM Oral)

0.5 mg (per each): $0.75

1 mg (per each): $0.86

2 mg (per each): $1.18

Tablets (KlonoPIN Oral)

0.5 mg (per each): $3.06

1 mg (per each): $3.49

2 mg (per each): $4.84

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Aklonil (TR);
  • Amotril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);
  • Antaspan (VN);
  • Antelepsin (HU);
  • Anzatax (PE);
  • Apetryl (EG);
  • Clonapilep (MX);
  • Clonaril (TH);
  • Clonatril (JO);
  • Clonatryl (CO);
  • Clonazepamum (HU);
  • Clonex (IL);
  • Clonium (BD);
  • Clonopam (TW);
  • Clonotril (CY, HK, MT, PH, SG, TR);
  • Clozapam (BD);
  • Clozer (MX);
  • Convolsil (TH);
  • Coquan (CO);
  • Iktorivil (SE);
  • Jing Kang (CN);
  • Kenoket (MX);
  • Klozepam (EG);
  • Kriadex (MX);
  • Leptic (BD);
  • Lonazep (IN);
  • Naza (LK);
  • Neuryl (EC, LK);
  • Paxam (AU, NZ);
  • Povanil (TH);
  • Ravotril (CL);
  • Riklona (ID);
  • Rivatril (FI);
  • Rivopam (SG);
  • Rivoram (JO);
  • Rivotril (AE, AR, AT, AU, BD, BE, BG, BH, BO, BR, CH, CY, CZ, DE, DK, EC, EE, ES, FR, GH, GR, HK, HR, HU, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LK, LT, LU, LY, MX, MY, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, PY, QA, RO, SA, SG, SI, SK, SY, TR, TW, TZ, UG, UY, VE, VN, YE, ZM, ZW);
  • Ronatril (EG);
  • Valpax (CL, PY);
  • Xetril (BD);
  • Zepanc (TW);
  • Zymanta (MX)


For country abbreviations used in Lexicomp (show table)

REFERENCES

  1. <800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.
  2. 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi:10.1111/jgs.15767 [PubMed 30693946]
  3. American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2009. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed May 24, 2017.
  4. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377 [PubMed 27060684]
  5. Aurora RN, Zak RS, Maganti RK, et al; Standards of Practice Committee; American Academy of Sleep Medicine. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85-95. [PubMed 20191945]
  6. Authier N, Balayssac D, Sautereau M, et al. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr. 2009;67(6):408-413. doi:10.1016/j.pharma.2009.07.001 [PubMed 19900604]
  7. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403‐439. doi:10.1177/0269881114525674 [PubMed 24713617]
  8. Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD, and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77‐84. doi:10.3109/13651501.2012.667114 [PubMed 22540422]
  9. Bank AM, Lee JW, Krause P, Berkowitz AL. What to do when patients with epilepsy cannot take their usual oral medications. Pract Neurol. 2017;17(1):66‐70. doi:10.1136/practneurol-2016-001437 [PubMed 28073923]
  10. Bergman U, Rosa FW, Baum C, Wiholm BE, Faich GA. Effects of exposure to benzodiazepine during fetal life. Lancet. 1992;340(8821):694-696. [PubMed 1355799]
  11. Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Ménière's disease. Otolaryngol Head Neck Surg. 2020;162(suppl 2):S1-S55. doi:10.1177/0194599820909438 [PubMed 32267799]
  12. Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). Otolaryngol Head Neck Surg. 2017;156(3)(suppl):S1‐S47. doi:10.1177/0194599816689667 [PubMed 28248609]
  13. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463-469. doi:10.1212/WNL.0b013e31829d86b6 [PubMed 23897874]
  14. Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series. Pediatrics. 1999;104(1):e11. [PubMed 10390297]
  15. Blin O, Simon N, Jouve E, et al. Pharmacokinetic and pharmacodynamic analysis of sedative and amnesic effects of lorazepam in healthy volunteers. Clin Neuropharmacol. 2001;24(2):71-81. doi:10.1097/00002826-200103000-00002 [PubMed 11307041]
  16. Bond AJ. Drug-induced behavioural disinhibition: Incidence, mechanisms and therapeutic implications.CNS Drugs. 1998;9(1):41-57.
  17. Bond A, Lader M. Differential effects of oxazepam and lorazepam on aggressive responding. Psychopharmacology (Berl). 1988;95(3):369-373. doi:10.1007/BF00181949 [PubMed 3137624]
  18. Bressman S, Fahn S. Essential myoclonus. Adv Neurol. 1986;43:287‐294. [PubMed 3080850]
  19. Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure. 1997;6(3):159-174. doi:10.1016/s1059-1311(97)80001-5 [PubMed 9203243]
  20. Brogden RN, Goa KL. Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity, and therapeutic use. Drugs. 1988;35(4):448-467. [PubMed 2839329]
  21. Buchanan N, Sharpe C. Clonazepam withdrawal in 13 patients with active epilepsy and drug side effects. Seizure. 1994;3(4):271-275. doi:10.1016/s1059-1311(05)80174-8 [PubMed 7894837]
  22. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986;315(14):854-859. doi:10.1056/NEJM198610023151403 [PubMed 3092053]
  23. Bystritsky A. Pharmacotherapy for generalized anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 13, 2020.
  24. Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998;26(4):676-684. doi:10.1097/00003246-199804000-00015 [PubMed 9559604]
  25. Caviness JN. Treatment of myoclonus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 8, 2020.
  26. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(suppl 5):7-12. [PubMed 15078112]
  27. Clonazepam orally disintegrating tablets [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; January 2021.
  28. Commander M, Green SH, Prendergast M. Behavioural disturbances in children treated with clonazepam. Dev Med Child Neurol. 1991;33(4):362-363. doi:10.1111/j.1469-8749.1991.tb14889.x [PubMed 1904374]
  29. Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89(5):283-306. doi:10.1159/000506868 [PubMed 32259826]
  30. Curran HV. Benzodiazepines, memory and mood: a review. Psychopharmacology (Berl). 1991;105(1):1-8. doi:10.1007/BF02316856 [PubMed 1684055]
  31. Davanzo R, Dal Bo S, Bua J, Copertino M, Zanelli E, Matarazzo L. Antiepileptic drugs and breastfeeding. Ital J Pediatr. 2013;39:50. [PubMed 23985170]
  32. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13(6):423‐428. [PubMed 8120156]
  33. Dawson J, Boyle J, Stanley N, Johnsen S, Hindmarch I, Skene DJ. Benzodiazepine-induced reduction in activity mirrors decrements in cognitive and psychomotor performance. Hum Psychopharmacol. 2008;23(7):605-13. doi:10.1002/hup.961 [PubMed 18570226]
  34. Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: A systematic review. Maturitas. 2017;101:17-22. doi:10.1016/j.maturitas.2017.04.002 [PubMed 28539164]
  35. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs. 2008;22(12):1021-1036. [PubMed 18998740]
  36. Edwards VE. Side effects of clonazepam therapy. Proc Aust Assoc Neurol. 1974;11:199-202. [PubMed 4219957]
  37. Fang M, Chen H, Li LH, et al. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. Int Clin Psychopharmacol. 2012;27(2):107‐113. doi:10.1097/YIC.0b013e32834fc431 [PubMed 22233697]
  38. Fernández-Arcos A, Iranzo A, Serradell M, Gaig C, Santamaria J. The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients. Sleep. 2016;39(1):121‐132. doi:10.5665/sleep.5332 [PubMed 26940460]
  39. Fisher JB, Edgren BE, Mammel MC, Coleman JM. Neonatal apnea associated with maternal clonazepam therapy: a case report. Obstet Gynecol. 1985;66(3)(suppl):34S-35S. [PubMed 4022513]
  40. Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 17, 2021.
  41. Ganança MM, Caovilla HH, Ganança FF, et al. Clonazepam in the pharmacological treatment of vertigo and tinnitus. Int Tinnitus J. 2002;8(1):50‐53. [PubMed 14763236]
  42. Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17(2):86‐128. doi:10.3109/15622975.2015.1132007 [PubMed 26912127]
  43. Giersch A, Boucart M, Elliott M, Vidailhet P. Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010;126(1):94-108. doi:10.1016/j.pharmthera.2010.01.004 [PubMed 20138190]
  44. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214-223. [PubMed 23789008]
  45. Guina J, Merrill B. Benzodiazepines I: Upping the care on downers: The evidence of risks, benefits and alternatives. J Clin Med. 2018;7(2):17. doi:10.3390/jcm7020017 [PubMed 29385731]
  46. Hanson RA, Menkes JH. A new anticonvulsant in the management of minor motor seizures. Dev Med Child Neurol. 1972;14(1):3-14. [PubMed 4554096]
  47. Harden CL, Meador KJ, Pennell PB, et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133-141. [PubMed 19398681]
  48. Ho TT, Gupta SV, Sanchez-Valle A. Prolonged clonazepam-induced withdrawal symptoms in an NAT2 ultraslow acetylator. Pharmacogenomics. 2019;20(2):69-73. doi:10.2217/pgs-2018-0145 [PubMed 30520338]
  49. Howell M, Schenck CH. Rapid eye movement sleep behavior disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 23, 2021.
  50. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53(1):39-49. [PubMed 11773648]
  51. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  52. Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol. 1986;43(10):1025‐1031. doi:10.1001/archneur.1986.00520100039012 [PubMed 3753263]
  53. Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. Eur Neuropsychopharmacol. 2015;25(11):1906-1913. doi:10.1016/j.euroneuro.2015.08.014 [PubMed 26342397]
  54. Johnson GD. Medical management of migraine-related dizziness and vertigo. Laryngoscope. 1998;108(1, pt 2):1‐28. doi:10.1097/00005537-199801001-00001 [PubMed 9430502]
  55. Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. Am J Ment Retard. 2002;107(5):376-410. doi:10.1352/0895-8017(2002)107<0376:BBSERA>2.0.CO;2 [PubMed 12186578]
  56. Kales A, Manfredi RL, Vgontzas AN, Baldassano CF, Kostakos K, Kales JD. Clonazepam: sleep laboratory study of efficacy and withdrawal. J Clin Psychopharmacol. 1991;11(3):189-193. [PubMed 2066457]
  57. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1 [PubMed 25081580]
  58. Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr. 2012;161(3):448-451. [PubMed 22504099]
  59. Keränen T, Sivenius J. Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. Acta Neurol Scand Suppl. 1983;97:69-80. doi:10.1111/j.1600-0404.1983.tb01536.x [PubMed 6424398]
  60. Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson' s Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.
  61. Klonopin tablets (clonazepam) [prescribing information]. Montgomery, AL: H2-Pharma LLC; December 2021.
  62. Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. [PubMed 26344706]
  63. Li SX, Lam SP, Zhang J, et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 2016;21:114‐120. doi:10.1016/j.sleep.2015.12.020 [PubMed 27448481]
  64. Liang TL, Tarsy D. Tardive dyskinesia: prevention, prognosis, and treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 4, 2021.
  65. Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication. Am J Psychiatry. 1991;148(8):1099-100. doi:10.1176/ajp.148.8.1099a [PubMed 1677237]
  66. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004;24(9):1177-1185. doi:10.1592/phco.24.13.1177.38089 [PubMed 15460178]
  67. Marder S, Davis M. Clinical manifestations, differential diagnosis, and initial management of psychosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 10, 2020.
  68. Mejo SL. Anterograde amnesia linked to benzodiazepines. Nurse Pract. 1992;17(10):44, 49-50. doi:10.1097/00006205-199210000-00013 [PubMed 1357612]
  69. Mojtabai R. Brief psychotic disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 10, 2020.
  70. Montagna P, Provini F, Plazzi G, Liguori R, Lugaresi E. Propriospinal myoclonus upon relaxation and drowsiness: a cause of severe insomnia. Mov Disord. 1997;12(1):66‐72. doi:10.1002/mds.870120112 [PubMed 8990056]
  71. Nardi AE, Freire RC, Valença AM, et al. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010;30(3):290-293. doi:10.1097/JCP.0b013e3181dcb2f3 [PubMed 20473065]
  72. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol. 1999;6(2):69-83. [PubMed 10519733]
  73. O'Boyle CA. Benzodiazepine-induced amnesia and anaesthetic practice: a review. Psychopharmacol Ser. 1988;6:146-165. [PubMed 2905804]
  74. Obeso JA, Artieda J, Rothwell JC, Day B, Thompson P, Marsden CD. The treatment of severe action myoclonus. Brain. 1989;112(pt 3):765‐777. doi:10.1093/brain/112.3.765 [PubMed 2499399]
  75. Oldham MA, Desan PH. Alcohol and sedative-hypnotic withdrawal catatonia: Two case reports, systematic literature review, and suggestion of a potential relationship with alcohol withdrawal delirium. Psychosomatics. 2016;57(3):246-255. doi:10.1016/j.psym.2015.12.007 [PubMed 26949118]
  76. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123(pt 2):331‐339. doi:10.1093/brain/123.2.331 [PubMed 10648440]
  77. Pandit SK, Heisterkamp DV, Cohen PJ. Further studies of the anti-recall effect of lorazepam: A dose--time--effect relationship. Anesthesiology. 1976;45(5):495-500. [PubMed 9845]
  78. Park TW. Benzodiazepine use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 16, 2021.
  79. Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526-548. doi:10.1097/FTD.0000000000000546 [PubMed 29957667]
  80. Pinder RM, Brogden RN, Speight TM, Avery GS. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 1976;12(5):321-361. doi:10.2165/00003495-197612050-00001 [PubMed 976134]
  81. Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014;171(1):44‐53. doi:10.1176/appi.ajp.2013.12101353 [PubMed 24399428]
  82. Reddy MSS, Achary U, Harbishettar V, Sivakumar PT, Varghese M. Paradoxical reaction to benzodiazepines in elderly - Case series. Asian J Psychiatr. 2018;35:8-10. doi:10.1016/j.ajp.2018.04.037 [PubMed 29723722]
  83. Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64(6):388-399. doi:10.1177/0706743719828968 [PubMed 30791698]
  84. Richardson JK, Eckner JT, Kim H, Ashton-Miller JA. A clinical method of evaluating simple reaction time and reaction accuracy is sensitive to a single dose of lorazepam. J Psychopharmacol. 2020;34(8):920-925. doi:10.1177/0269881120915409 [PubMed 32536331]
  85. Rivotril (clonazepam) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Ltd; January 2018.
  86. Rothschild AJ, Shindul-Rothschild JA, Viguera A, Murray M, Brewster S. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol. 2000;20(1):7-11. doi:10.1097/00004714-200002000-00003 [PubMed 10653202]
  87. Roy-Byrne PP. Pharmacotherapy for panic disorder with or without agoraphobia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 8, 2020a.
  88. Roy-Byrne PP, Craske M. Approach to treating panic disorder with or without agoraphobia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 19, 2020b.
  89. Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. Int J Geriatr Psychiatry. 2018;33(4):583-590. doi:10.1002/gps.4821 [PubMed 29143367]
  90. Schachter SC. Antiseizure drugs: mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 8, 2020.
  91. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004;65(2):244‐248. [PubMed 15003080]
  92. Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodiazepines--a genetically determined phenomenon? Anaesth Intensive Care. 1987;15(3):330-331. doi:10.1177/0310057X8701500314 [PubMed 3661967]
  93. Söderman P, Matheson I. Clonazepam in breast milk. Eur J Pediatr. 1988;147(2):212-213. [PubMed 3366144]
  94. Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. Eur J Clin Pharmacol. 2014;70(11):1361-1366. [PubMed 25183382]
  95. Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 10, 2020.
  96. Sugai K. Seizures with clonazepam: discontinuation and suggestions for safe discontinuation rates in children. Epilepsia. 1993;34(6):1089‐1097. doi:10.1111/j.1528-1157.1993.tb02138.x [PubMed 8243361]
  97. Sylvestre MP, Abrahamowicz M, Čapek R, Tamblyn R. Assessing the cumulative effects of exposure to selected benzodiazepines on the risk of fall-related injuries in the elderly. Int Psychogeriatr. 2012;24(4):577-586. doi:10.1017/S1041610211002031 [PubMed 22059800]
  98. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445-451. doi:10.1176/ajp.147.4.445 [PubMed 1969244]
  99. Tijssen MA, Schoemaker HC, Edelbroek PJ, Roos RA, Cohen AF, van Dijk JG. The effects of clonazepam and vigabatrin in hyperekplexia. J Neurol Sci. 1997;149(1):63‐67. doi:10.1016/s0022-510x(97)05378-1 [PubMed 9168167]
  100. Tsuda M, Shimizu N, Suzuki T. Contribution of glutamate receptors to benzodiazepine withdrawal signs. Jpn J Pharmacol. 1999;81(1):1-6. doi:10.1254/jjp.81.1 [PubMed 10580363]
  101. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf. Updated September 2016. Accessed October 5, 2016.
  102. US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf. Updated June 2017. Accessed March 16, 2020.
  103. US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of substance use disorders. https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf. Updated December 2015. Accessed March 16, 2021.
  104. van Laar M, Volkerts E, Verbaten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl). 2001;154(2):189-197. doi:10.1007/s002130000633 [PubMed 11314681]
  105. Veiby G, Bjørk M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. Seizure. 2015;28:57-65. [PubMed 25837494]
  106. Vinkers CH, Olivier B. Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future For Subtype-Selective GABA(A) Receptor Modulators? Adv Pharmacol Sci. 2012;2012:416864. [PubMed 22536226]
  107. Walson PD, Edge JH. Clonazepam disposition in pediatric patients. Ther Drug Monit. 1996;18(1):1-5. [PubMed 8848810]
  108. Waslick B. Psychopharmacology interventions for pediatric anxiety disorders: a research update. Child Adolesc Psychiatr Clin N Am. 2006;15(1):51-71. doi:10.1016/j.chc.2005.08.009 [PubMed 16321725]
  109. Wang SM, Kim JB, Sakong JK, et al. The efficacy and safety of clonazepam in patients with anxiety disorder taking newer antidepressants: a multicenter naturalistic study. Clin Psychopharmacol Neurosci. 2016;14(2):177‐183. doi:10.9758/cpn.2016.14.2.177 [PubMed 27121429]
  110. Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(11):1203-1210. [PubMed 17894421]
  111. Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol. 1990;29(2):169-177. doi:10.1111/j.1365-2125.1990.tb03616.x [PubMed 2106335]
  112. Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol. 2019;33(8):923-947. doi:10.1177/0269881119855343 [PubMed 31271339]
  113. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. West J Emerg Med. 2012;13(1):26‐34. doi:10.5811/westjem.2011.9.6866 [PubMed 22461918]
  114. Wlodarczyk BJ, Palacios AM, George TM, Finnell RH. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A. 2012;158A(8):2071-2090. [PubMed 22711424]
  115. Wolf B, Griffiths RR. Physical dependence on benzodiazepines: differences within the class. Drug Alcohol Depend. 1991;29(2):153-156. doi:10.1016/0376-8716(91)90044-y [PubMed 1686752]
  116. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
  117. Wusthoff CJ, Shellhaas RA, Licht DJ. Management of common neurologic symptoms in pediatric palliative care: seizures, agitation, and spasticity. Pediatr Clin North Am. 2007;54(5):709-733. [PubMed 17933619]
Topic 9284 Version 503.0